163 related articles for article (PubMed ID: 27473279)
1. Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment-A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability.
Maretti E; Rustichelli C; Romagnoli M; Balducci AG; Buttini F; Sacchetti F; Leo E; Iannuccelli V
Int J Pharm; 2016 Sep; 511(1):669-679. PubMed ID: 27473279
[TBL] [Abstract][Full Text] [Related]
2. Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy.
Maretti E; Costantino L; Rustichelli C; Leo E; Croce MA; Buttini F; Truzzi E; Iannuccelli V
Int J Pharm; 2017 Aug; 528(1-2):440-451. PubMed ID: 28624659
[TBL] [Abstract][Full Text] [Related]
3. Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy.
Maretti E; Costantino L; Buttini F; Rustichelli C; Leo E; Truzzi E; Iannuccelli V
Drug Deliv Transl Res; 2019 Feb; 9(1):298-310. PubMed ID: 30484257
[TBL] [Abstract][Full Text] [Related]
4. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Rawal T; Parmar R; Tyagi RK; Butani S
Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
[TBL] [Abstract][Full Text] [Related]
5. Spray freeze drying for dry powder inhalation of nanoparticles.
Ali ME; Lamprecht A
Eur J Pharm Biopharm; 2014 Aug; 87(3):510-7. PubMed ID: 24657824
[TBL] [Abstract][Full Text] [Related]
6. Effect of freeze-drying, cryoprotectants and storage conditions on the stability of secondary structure of insulin-loaded solid lipid nanoparticles.
Soares S; Fonte P; Costa A; Andrade J; Seabra V; Ferreira D; Reis S; Sarmento B
Int J Pharm; 2013 Nov; 456(2):370-81. PubMed ID: 24036086
[TBL] [Abstract][Full Text] [Related]
7. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.
Nemati E; Mokhtarzadeh A; Panahi-Azar V; Mohammadi A; Hamishehkar H; Mesgari-Abbasi M; Ezzati Nazhad Dolatabadi J; de la Guardia M
AAPS PharmSciTech; 2019 Feb; 20(3):120. PubMed ID: 30796625
[TBL] [Abstract][Full Text] [Related]
8. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
Momin MAM; Tucker IG; Das SC
Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
[TBL] [Abstract][Full Text] [Related]
9. Preparation, optimization, and in vitro simulated inhalation delivery of carvedilol nanoparticles loaded on a coarse carrier intended for pulmonary administration.
Abdelbary AA; Al-mahallawi AM; Abdelrahim ME; Ali AM
Int J Nanomedicine; 2015; 10():6339-53. PubMed ID: 26491298
[TBL] [Abstract][Full Text] [Related]
10. Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties.
Levet V; Merlos R; Rosière R; Amighi K; Wauthoz N
Int J Pharm; 2017 Jan; 517(1-2):359-372. PubMed ID: 28007545
[TBL] [Abstract][Full Text] [Related]
11. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance.
Ezzati Nazhad Dolatabadi J; Hamishehkar H; Valizadeh H
Drug Dev Ind Pharm; 2015; 41(9):1431-7. PubMed ID: 25220930
[TBL] [Abstract][Full Text] [Related]
12. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy.
Rosière R; Van Woensel M; Mathieu V; Langer I; Mathivet T; Vermeersch M; Amighi K; Wauthoz N
Int J Pharm; 2016 Mar; 501(1-2):148-59. PubMed ID: 26850313
[TBL] [Abstract][Full Text] [Related]
14. Development of controlled-release cisplatin dry powders for inhalation against lung cancers.
Levet V; Rosière R; Merlos R; Fusaro L; Berger G; Amighi K; Wauthoz N
Int J Pharm; 2016 Dec; 515(1-2):209-220. PubMed ID: 27737810
[TBL] [Abstract][Full Text] [Related]
15. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance.
Patil-Gadhe A; Kyadarkunte A; Patole M; Pokharkar V
Eur J Pharm Biopharm; 2014 Sep; 88(1):169-77. PubMed ID: 25078860
[TBL] [Abstract][Full Text] [Related]
16. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles.
Wang Y; Kho K; Cheow WS; Hadinoto K
Int J Pharm; 2012 Mar; 424(1-2):98-106. PubMed ID: 22226876
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for pulmonary delivery.
Varshosaz J; Hassanzadeh F; Mardani A; Rostami M
Pharm Dev Technol; 2015 Mar; 20(2):183-96. PubMed ID: 24219091
[TBL] [Abstract][Full Text] [Related]
18. Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline.
Rawal T; Patel S; Butani S
Eur J Pharm Sci; 2018 Nov; 124():273-287. PubMed ID: 30176365
[TBL] [Abstract][Full Text] [Related]
19. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
Cheow WS; Ng ML; Kho K; Hadinoto K
Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
[TBL] [Abstract][Full Text] [Related]
20. [Development of Inhalable Dry Powder Formulations Loaded with Nanoparticles Maintaining Their Original Physical Properties and Functions].
Okuda T
Yakugaku Zasshi; 2017; 137(11):1339-1348. PubMed ID: 29093369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
